NI201500094A - Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos. - Google Patents
Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.Info
- Publication number
- NI201500094A NI201500094A NI201500094AA NI201500094A NI201500094A NI 201500094 A NI201500094 A NI 201500094A NI 201500094A A NI201500094A A NI 201500094AA NI 201500094 A NI201500094 A NI 201500094A NI 201500094 A NI201500094 A NI 201500094A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pyrrolopyrimidine
- compositions
- methods
- treatment
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Se proporcionan en la presente compuestos de Pirrolopirimidina que tienen la siguiente estructura: en donde R1, R2, R3, y L son como se definen en la presente, composiciones que comprenden una cantidad efectiva de un compuesto de Pirrolopirimidina, y métodos para tratar o prevenir el cáncer de seno, más particularmente el cáncer de seno triple negativo, que comprende administrar una cantidad efectiva de tales compuestos de Pirrolopirimidina a un sujeto en necesidad de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361753259P | 2013-01-16 | 2013-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201500094A true NI201500094A (es) | 2015-09-21 |
Family
ID=50031611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201500094AA NI201500094A (es) | 2013-01-16 | 2015-07-15 | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos. |
Country Status (24)
Country | Link |
---|---|
US (3) | US9346812B2 (es) |
EP (2) | EP3202403A1 (es) |
JP (1) | JP2016505041A (es) |
KR (1) | KR20150108389A (es) |
CN (1) | CN105188704B (es) |
AR (1) | AR094494A1 (es) |
AU (1) | AU2014207641A1 (es) |
BR (1) | BR112015016997A2 (es) |
CA (1) | CA2897985A1 (es) |
CL (1) | CL2015001990A1 (es) |
EA (1) | EA201591327A1 (es) |
EC (1) | ECSP15030799A (es) |
ES (1) | ES2638179T3 (es) |
HK (1) | HK1212207A1 (es) |
IL (1) | IL239901A0 (es) |
MX (1) | MX2015009209A (es) |
NI (1) | NI201500094A (es) |
NZ (1) | NZ630467A (es) |
PE (1) | PE20151995A1 (es) |
PH (1) | PH12015501576A1 (es) |
SG (1) | SG11201505446WA (es) |
TW (1) | TW201441227A (es) |
WO (1) | WO2014113429A2 (es) |
ZA (1) | ZA201505011B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
KR20170024120A (ko) * | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
WO2016073771A2 (en) * | 2014-11-06 | 2016-05-12 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
CN107801397B (zh) | 2015-02-13 | 2021-07-30 | 达纳-法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
CN105906630B (zh) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
JP6819585B2 (ja) * | 2015-06-22 | 2021-01-27 | 小野薬品工業株式会社 | Brk阻害化合物 |
WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
JP6541871B2 (ja) * | 2015-08-13 | 2019-07-10 | 北京韓美薬品有限公司 | Irak4阻害剤、及びその応用 |
EP3362452A4 (en) | 2015-10-13 | 2019-06-12 | The Scripps Research Institute | THERAPEUTIC TARGETING OF CASEINKINASE-1 IN BREAST CANCER |
RU2018120728A (ru) | 2015-11-06 | 2019-12-09 | СЭМЬЮМЕД, ЭлЭлСи | Лечение остеоартрита |
CN105646496B (zh) * | 2016-01-20 | 2018-07-20 | 华侨大学 | 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用 |
CN108727400B (zh) * | 2017-05-24 | 2021-07-09 | 四川晶华生物科技有限公司 | 一种治疗肿瘤的化合物 |
JP7250011B2 (ja) * | 2017-10-27 | 2023-03-31 | バイエル アクチェンゲゼルシャフト | P2x3阻害剤としての新規なピラゾロ-ピロロ-ピリミジン-ジオン誘導体 |
EP3731845A4 (en) * | 2017-12-28 | 2021-10-06 | Development Center for Biotechnology | HETEROCYCLIC COMPOUNDS AS TYRO3, AXL AND MERTK (TAM) FAMILY OF RECEPTOR TYROSINKINASE INHIBITORS |
ES2922633T3 (es) | 2017-12-28 | 2022-09-19 | Daewoong Pharmaceutical Co Ltd | Derivado de oxi-fluoropiperidina como inhibidor de cinasa |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
WO2019222385A1 (en) | 2018-05-15 | 2019-11-21 | University Of Tennessee Research Foundation | Compounds for treatment of triple negative breast cancer and ovarian cancer |
US20230000842A1 (en) | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
EP4332104A1 (en) * | 2021-04-30 | 2024-03-06 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
EP4335441A1 (en) * | 2021-05-03 | 2024-03-13 | JBKLAB Co., Ltd. | Pharmaceutical composition for preventing, alleviating, or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | 2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法 |
DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
TW274550B (es) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
ATE281834T1 (de) | 1997-09-26 | 2004-11-15 | Zentaris Gmbh | Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | 2−アリールプリン−9−アセトアミド誘導体 |
JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬 |
JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | 2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体 |
US20050033048A1 (en) | 2000-12-12 | 2005-02-10 | Rajagopal Bakthavatchalam | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
IL160440A0 (en) | 2001-09-04 | 2004-07-25 | Boehringer Ingelheim Pharma | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
EP1438048A1 (en) | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
US20040204420A1 (en) | 2002-08-05 | 2004-10-14 | Rana Tariq M. | Compounds for modulating RNA interference |
WO2004041285A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
WO2004076454A1 (de) | 2003-02-26 | 2004-09-10 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
US20040213757A1 (en) | 2003-04-23 | 2004-10-28 | Wyeth Holdings Corporation | Water soluble wortmannin derivatives |
CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
EP1641423B1 (en) | 2003-06-26 | 2010-03-17 | Merck Sharp & Dohme Corp. | Benzodiazepine cgrp receptor antagonists |
EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | 2-アリールプリン誘導体の製造方法 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases |
WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
CN101048410B (zh) | 2004-10-29 | 2010-06-23 | 泰博特克药品有限公司 | 抑制hiv的双环嘧啶衍生物 |
SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
SI1853588T1 (sl) | 2005-02-16 | 2008-10-31 | Astrazeneca Ab | Kemične spojine |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
RU2007140903A (ru) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
EP2995619B1 (en) | 2006-08-02 | 2019-09-25 | Cytokinetics, Inc. | Certain chemical entities comprising imidazopyrimidines, compositions and methods |
US20100144738A1 (en) | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
AU2007338601C1 (en) | 2006-09-05 | 2014-07-24 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
CL2007002866A1 (es) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
KR20140104060A (ko) | 2006-10-19 | 2014-08-27 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
EP2078018B1 (en) | 2006-10-19 | 2012-03-14 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US20090258096A1 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer Methods Employing Extracts of Gleditsia sinensis Lam |
EP2271631B1 (en) | 2008-04-22 | 2018-07-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
EP2493472B1 (en) | 2009-10-26 | 2016-12-07 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
US20120028972A1 (en) | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
AU2012290056B2 (en) | 2011-08-03 | 2015-03-19 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for LKB1 status |
SG2014014450A (en) | 2011-09-22 | 2014-09-26 | Pfizer | Pyrrolopyrimidine and purine derivatives |
CN107157990B (zh) | 2011-10-19 | 2020-01-07 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
AU2012304276B2 (en) | 2011-12-02 | 2015-01-15 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
BR112014020786A2 (pt) | 2012-02-24 | 2020-10-27 | Signal Pharmaceuticals, Llc | método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência |
KR102057358B1 (ko) | 2012-03-15 | 2019-12-18 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
EP2825171B1 (en) | 2012-03-15 | 2018-03-14 | Signal Pharmaceuticals, LLC | Treatment of cancer with tor kinase inhibitors |
CN108992446A (zh) | 2012-03-15 | 2018-12-14 | 西格诺药品有限公司 | 用tor激酶抑制剂治疗癌症 |
ES2618007T3 (es) | 2012-08-06 | 2017-06-20 | Acea Biosciences, Inc. | Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
AU2013202768B2 (en) | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
-
2014
- 2014-01-15 SG SG11201505446WA patent/SG11201505446WA/en unknown
- 2014-01-15 EP EP17152166.9A patent/EP3202403A1/en not_active Withdrawn
- 2014-01-15 ES ES14702393T patent/ES2638179T3/es active Active
- 2014-01-15 EP EP14702393.1A patent/EP2945636B1/en not_active Not-in-force
- 2014-01-15 CA CA2897985A patent/CA2897985A1/en not_active Abandoned
- 2014-01-15 US US14/155,498 patent/US9346812B2/en active Active
- 2014-01-15 TW TW103101537A patent/TW201441227A/zh unknown
- 2014-01-15 KR KR1020157022134A patent/KR20150108389A/ko not_active Application Discontinuation
- 2014-01-15 AU AU2014207641A patent/AU2014207641A1/en not_active Abandoned
- 2014-01-15 EA EA201591327A patent/EA201591327A1/ru unknown
- 2014-01-15 CN CN201480015876.1A patent/CN105188704B/zh not_active Expired - Fee Related
- 2014-01-15 US US14/155,485 patent/US9428509B2/en active Active
- 2014-01-15 PE PE2015001346A patent/PE20151995A1/es not_active Application Discontinuation
- 2014-01-15 BR BR112015016997A patent/BR112015016997A2/pt not_active IP Right Cessation
- 2014-01-15 MX MX2015009209A patent/MX2015009209A/es unknown
- 2014-01-15 WO PCT/US2014/011612 patent/WO2014113429A2/en active Application Filing
- 2014-01-15 JP JP2015553794A patent/JP2016505041A/ja active Pending
- 2014-01-15 NZ NZ630467A patent/NZ630467A/en not_active IP Right Cessation
- 2014-01-15 AR ARP140100151A patent/AR094494A1/es unknown
-
2015
- 2015-07-12 IL IL239901A patent/IL239901A0/en unknown
- 2015-07-13 ZA ZA2015/05011A patent/ZA201505011B/en unknown
- 2015-07-15 NI NI201500094AA patent/NI201500094A/es unknown
- 2015-07-15 PH PH12015501576A patent/PH12015501576A1/en unknown
- 2015-07-15 CL CL2015001990A patent/CL2015001990A1/es unknown
- 2015-07-16 EC ECIEPI201530799A patent/ECSP15030799A/es unknown
-
2016
- 2016-01-04 HK HK16100005.5A patent/HK1212207A1/xx unknown
- 2016-07-21 US US15/215,728 patent/US9795607B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014113429A3 (en) | 2014-10-09 |
AR094494A1 (es) | 2015-08-05 |
ECSP15030799A (es) | 2015-11-30 |
MX2015009209A (es) | 2016-03-17 |
US20140200207A1 (en) | 2014-07-17 |
WO2014113429A2 (en) | 2014-07-24 |
JP2016505041A (ja) | 2016-02-18 |
IL239901A0 (en) | 2015-08-31 |
ZA201505011B (en) | 2016-11-30 |
EA201591327A1 (ru) | 2015-12-30 |
EP2945636A2 (en) | 2015-11-25 |
US9795607B2 (en) | 2017-10-24 |
ES2638179T3 (es) | 2017-10-19 |
CL2015001990A1 (es) | 2016-01-22 |
KR20150108389A (ko) | 2015-09-25 |
CN105188704A (zh) | 2015-12-23 |
US20140200206A1 (en) | 2014-07-17 |
PE20151995A1 (es) | 2016-01-13 |
US9346812B2 (en) | 2016-05-24 |
US9428509B2 (en) | 2016-08-30 |
TW201441227A (zh) | 2014-11-01 |
CA2897985A1 (en) | 2014-07-24 |
AU2014207641A1 (en) | 2015-08-06 |
EP3202403A1 (en) | 2017-08-09 |
NZ630467A (en) | 2017-02-24 |
US20160324861A1 (en) | 2016-11-10 |
BR112015016997A2 (pt) | 2017-07-11 |
SG11201505446WA (en) | 2015-08-28 |
HK1212207A1 (en) | 2016-06-10 |
EP2945636B1 (en) | 2017-06-28 |
PH12015501576A1 (en) | 2016-02-01 |
CN105188704B (zh) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201500094A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos. | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
BR112015011830A2 (pt) | compostos e seus métodos de utilização | |
GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
NI201500140A (es) | Compuestos y composiciones terapéuticos | |
CU20170099A7 (es) | Terapias de combinación para el tratamiento de cánceres | |
UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
GT201400187A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
PE20210949A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados | |
AR087918A1 (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
GT201500247A (es) | Imidazopiridazinas sustituidas | |
DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
ECSP14011792A (es) | Inhibidores de iap | |
BR112017008481A2 (pt) | composto antimicótico | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
SG10201900564WA (en) | Methods for treating cancer | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
EA201591434A1 (ru) | Способ обеспечения глазной нейропротекции |